Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist[1] that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials[2] and was subsequently discontinued.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H15N5 |
Molar mass | 193.254 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
See also
editReferences
edit- ^ Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J (June 1998). "In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro". Psychopharmacology. 137 (3): 233–240. doi:10.1007/s002130050615. PMID 9683000. S2CID 20740372. Archived from the original on 2000-10-02. Retrieved 2009-12-03.
- ^ Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR (1998). "A bridging study of LU 25-109 in patients with probable Alzheimer's disease". Life Sciences. 62 (3): 195–202. doi:10.1016/S0024-3205(97)01087-4. PMID 9488097.